Heart rate reduction by pharmacological If current inhibition

Advances in Cardiology

Volumn 43, Issue , 2006, Pages 31-44

  Cargnoni, A ^a   Ceconi, C ^a   Stavroula, G ^a   Ferrari, R ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAZEPINE DERIVATIVE; CARDIOTONIC AGENT; ION CHANNEL; IVABRADINE;

CARDIOVASCULAR DISEASE; DIASTOLE; DRUG EFFECT; HEART CONTRACTION; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

BENZAZEPINES; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DIASTOLE; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; ION CHANNELS; MYOCARDIAL CONTRACTION;

EID: 33747882866     PISSN: 00652326     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000095404     Document Type: Review

References (38)

1. K, in Purkinje fibres. J Physiol 1980;308:353-367.
2. DiFrancesco D: A study of ionic nature of the pace-maker current in calf Purkinje fibres. J Physiol 1981;314:377-393.
3. Ogiwara Y, Furukawa Y, Akahane K, et al: Bradycardic effects of AQ-A 39 (falipamil) in situ and in isolated, blood-perfused dog hearts. Comparison with alinidine and verapamil. Jpn Heart J 1988;29:849-861.
4. f) in guinea-pig dissociated sinoatrial node cells. Br J Pharmacol 1993;110:343-349.
5. Thollon C, Cambarrat C, Vian J, et al: Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparisons with UL-FS 49. Br J Pharmacol 1994;112:37-42.
6. Krumpl G, Mayer N, Schneider W, Raberger G: Effects of alinidine exercise-induced regional contractile dysfunction in dogs. Eur J Pharmacol 1986;130:37-46.
7. Schamhardt HC, Verdouw PD, Saxena PR: Improvement of perfusion and function of ischaemic porcine myocardium after reduction of heart rate by alinidine. J Cardiovasc Pharmacol 1981;3:728-738.
8. Schulz R, Rose J, Skyschally A, Heusch G: Bradycardic agent UL-FS 49 attenuates ischemic regional dysfunction and reduces infarct size in swine: comparison with the β-blocker atenolol. J Cardiovasc Pharmacol 1995;25:216-228.
9. f inhibition: expected clinical benefits from pure heart rate reduction in coronary patients. Eur Heart J 2005;7:H16-H21.
10. f channels by ivabradine. J Gen Physiol 2002;120:1-13.
11. f Channels Inhibition in Cardiology. London, Science Press Ltd, 2004, pp 1-13.
12. Thollon C, Bidouard JP, Cambarrat C, et al: Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S16257. Eur J Pharmacol 1997;339:43-51.
13. Bois P, Bescond J, Renaudon B, Lenfant J: Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996;118:1051-1057.
14. f current inhibitor. Eur Heart J 2003;5:G26-G35.
15. Vilaine JP, Bidouard JP, Lesage L, et al: Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol 2003;42:688-696.
16. Colin P, Ghaleh B, Monnet X, et al: Contribution of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 2003;284:H676-H682.
17. Simon L, Ghaleh B, Puybasset L, et al: Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995;275:659-666.
18. Opie LH: The Heart: Physiology and Metabolism. New York, Raven Press, 1991.
19. Balaban RS: Regulation of oxidative phosphorylation in the mammalian cell. Am J Physiol 1990;258:C377-C389.
20. Kjekshus J: Importance of heart rate in determining β-blocker efficacy in acute and long-term myocardial infarction intervention. Am J Cardiol 1986;57:43F-49F.
21. The Multicenter Diltiazem Postinfarction Trial Research Group: Effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392.
22. The Danish Study Group on Verapamil in Myocardial Infarction: Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol 1990;66:779-785.
23. Furberg CD, Hawkins CM, Lichstein E, for the Beta-Blocker Heart Attack Trial Study Group: Effect of propranolol in postinfarction patients with mechanical or electrical complications. Circulation 1984;69:761-765.
24. Monnet X, Colin P, Ghelch B, et al: Heart rate reduction during exercise-induced myocardial ischaemia and stunning. Eur Heart J 2004;25:579-586.
25. f current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109:1674-1679.
26. Jondeau G, Korewicki J, Vasiliauskns D: Effect of ivabradine in patients with left ventricular systolic dysfunction and coronary artery disease (abstract 2637). Eur Heart J Suppl 2004;25:491.
27. f current inhibition with ivabradine. Drugs 2004;64:1757-1765.
28. Heidland UE, Stauer BE: Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001;104:1477-1482.
29. f in ventricular myocytes isolated from hypertensive rats. J Physiol 1994;481:585-591.
30. f in ventricular myocytes from normotensive and hypertensive rats during aging. Circulation 1996;94:1674-1681.
31. Stilli D, Sgoifo A, Macchi E, et al: Myocardial remodeling and arrhythmogenesis in moderate cardiac hypertrophy in rats. Am J Physiol Heart Circ Physiol 2001;280:H142-H150.
32. f) and hyperpolarization-activated cyclic nucleotide-gated channel mRNA expression in ventricular cells from control and hypertrophied rat hearts. J Physiol 2003;553:395-405.
33. Sartiani L, Cerbai E, DePaoli P, et al: The expression and pharmacological modulation of the pacemaker current in ventricular myocytes from postmyocardial infarction. Circulation 2000;102:129.
34. Shi VI, Whymore R, Yu H, et al: Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues. Circ Res 1999;B5:e1-e6.
35. Pachucki J, Burmeister LA, Larsen PR: Thyroid hormone regulates hyperpolarization-activated cyclic nucleotide-gated channel (HCN2) mRNA in the rat heart. Circ Res 1999;85:498-503.
36. 2- adrenoceptor overexpressing mice. Naunyn Schmiedebergs Arch Pharmacol 2001;364:131-139.
37. f occurrence and properties in neonatal rat ventricular myocytes. Cardiovasc Res 1999;42:416-423.
38. f current and spontaneous activity in mouse embryonic ventricular myocytes. Circ Res 2001;88:536-542.